Lupin Ltd announced that Dr Raj Kamboj has joined the company as president - new chemical entity research. This reflects the company's commitment to continually strengthen its team by attracting the best talent globally.

Raj is an eminent scientist from the world of drug discovery. He is a PhD from University of Adelaide, Australia and joins Lupin from Xenon Pharmaceuticals Inc., Vancouver, where he had been working for the past five years. He has returned to India after 26 years and brings with him a wide range of experience in the field of drug discovery and clinical development. Prior to Xenon, he was working with Allelix, Canada. In both companies Raj was instrumental in taking the companies from the inception of the drug discovery group all the way to multiple licensing transactions and collaborations.

"We are very excited to have Raj join us as the chief of our drug discovery programme", Dr D B Gupta, chairman, Lupin Ltd. said. "He brings with him a vast pool of knowledge and experience which will be a great value add for Lupin's NCE research".

Lupin is committed to developing new and innovative healthcare products focusing on unmet needs. It has a pipeline of four Investigational New Drugs that focus on three different disease areas namely Migraine, Psoriasis and Tuberculosis. The company also has pre-clinical programmes in diabetes and Rheumatoid Arthritis.